Priprava i evaluacija novog derivata eritromicina – eritromicin taurat

Erythromycin taurate, a new derivative of erythromycin, was prepared by reacting the erythromycin base with tauric acid and its physico-chemical and biological properties were evaluated. The derivative has reasonably good solubility in organic solvents. The partition coefficient values in chloroform/water 1.17 and octanol/water 1.16 systems indicate its good distribution in various tissues in vivo. The in vitro antimicrobial potency of the derivative (833.33 microgramms per mg) is higher than the existing derivatives such as erythromycin estolate, erythromycin stearate, erythromycin ethyl succinate, erythromycin gluceptate, erythromycin lactobionate. The antimicrobial spectrum is comparable to that of the parent compound. Our results indicate that erythromycin taurate has a high potential for possible clinical application and is more efficient against Escherichia coli and Klebsiella pneumoniae than the parent base.Eritromicin taurat pripravljen je reakcijom eritromicin baze s taurinskom kiselinom. U radu su evaluirana fizičko-kemijska i biološka svojstva ovog novog derivata eritromicina. Eritromicin taurat je relativno dobro topljiv u organskim otapalima. Koeficijent razdjeljenja u sustavu kloroform/voda bio je 1,17 a u sustavu oktanol/voda 1,16 što ukazuje da se ova ljekovita tvar može dobro raspodijeliti u različitim tkivima in vivo. Antimikrobna aktivnost in vitro (833,33 g mg-1) je veća od aktivnosti postojećih derivata eritromicina: estolata, stearata, etil sukcinata, gluceptata, laktobionata. Spektar antimikrobnog djelovanja je sličan spektru samog eritromicina. Zbog svega toga moguća je klinička primjena eritromicin taurata

Priprava i evaluacija novog derivata eritromicina – eritromicin taurat

Erythromycin taurate, a new derivative of erythromycin, was prepared by reacting the erythromycin base with tauric acid and its physico-chemical and biological properties were evaluated. The derivative has reasonably good solubility in organic solvents. The partition coefficient values in chloroform/water 1.17 and octanol/water 1.16 systems indicate its good distribution in various tissues in vivo. The in vitro antimicrobial potency of the derivative (833.33 microgramms per mg) is higher than the existing derivatives such as erythromycin estolate, erythromycin stearate, erythromycin ethyl succinate, erythromycin gluceptate, erythromycin lactobionate. The antimicrobial spectrum is comparable to that of the parent compound. Our results indicate that erythromycin taurate has a high potential for possible clinical application and is more efficient against Escherichia coli and Klebsiella pneumoniae than the parent base.Eritromicin taurat pripravljen je reakcijom eritromicin baze s taurinskom kiselinom. U radu su evaluirana fizičko-kemijska i biološka svojstva ovog novog derivata eritromicina. Eritromicin taurat je relativno dobro topljiv u organskim otapalima. Koeficijent razdjeljenja u sustavu kloroform/voda bio je 1,17 a u sustavu oktanol/voda 1,16 što ukazuje da se ova ljekovita tvar može dobro raspodijeliti u različitim tkivima in vivo. Antimikrobna aktivnost in vitro (833,33 g mg-1) je veća od aktivnosti postojećih derivata eritromicina: estolata, stearata, etil sukcinata, gluceptata, laktobionata. Spektar antimikrobnog djelovanja je sličan spektru samog eritromicina. Zbog svega toga moguća je klinička primjena eritromicin taurata

Case Report Rapidly Progressive Atrioventricular Block in a Patient with Sarcoidosis

Cardiac sarcoidosis is a major cause of death in patients with systemic sarcoidosis. Cardiac manifestations are seen in 2.3% of the patients. Atrioventricular (AV) block is one of the common manifestations of cardiac sarcoidosis. Other presentations of cardiac involvement include congestive heart failure, ventricular arrhythmias, and sudden cardiac death. The presence of AV block in young patients should raise the suspicion of sarcoidosis. AV block may be the only manifestation and patients may not have clinical evidence of pulmonary involvement. Here we describe a young male presented with exercise induced AV block rapidly progressing to complete heart block with recurrent syncope needing urgent pacemaker implantation. Factors that suggested an infiltrative process included his young age, rapidly progressive conduction abnormalities in the ECG in the absence of coronary disease, and previous history of cutaneous sarcoidosis

A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients [version 1; peer review: 2 approved]

Background: Globally, alternative medicine is used widely by most patients for several health challenges. To evaluate the effectiveness and safety of PeaNoc XL Tablet in managing pain and inflammation, a randomized clinical trial and systematic study was designed. PeaNoc XL Tablet has been widely utilized for pain and inflammation management, but no previous studies have examined its efficacy and safety. The aim of this study was to determine the clinical effectiveness and safety profile of PeaNoc XL in patients with arthritis experiencing joint pain and inflammation. Methods: A randomized, controlled, and an open-label trial was conducted. A total of 155 patients (18 to 60 years) with arthritis were enrolled for participation. Using computer-generated random sequences, the study population was divided into two groups in a randomized manner. Group A received Standard therapy and Group B received Standard therapy with PeaNoc XL Tablet 400mg (two tablets OD after food). Results: Out of 155 patients, a total of 83 individuals were excluded from the study, leaving 72 patients who were randomly assigned to either Group A (n=36) or Group B (n=36). The administration of PeaNoc XL as an adjunct to standard therapy resulted in a significant reduction in levels of TNF-α (P<0.01), IL-1β (P<0.001), IL-6 (P<0.01), and CRP (P<0.01) in arthritis patients experiencing joint pain and inflammation. Conversely, no notable differences were observed from the baseline in the standard therapy group. Conclusions: After 12 weeks of supplementation of PeaNoc XL tablets, as an add-on therapy helps in the reduction of pain score, joint stiffness, and physical stiffness. Trial registration:  CTRI/2022/10/046693

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary.

S

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary.

S

withdrawn 2017 hrs ehra ecas aphrs solaece expert consensus statement on catheter and surgical ablation of atrial fibrillation

n/

Necessity of Herbal Medicine in the Management of Metabolic Syndrome

People are more susceptible to a variety of diseases based on their lifestyle and occupational patterns. Metabolic syndrome (MS) is a worldwide health issue that is linked to a variety of risk factors, including hyperglycemia, dyslipidemia, hypertension, and obesity. Herbal medicine has been used for a long time. Herbal medicines have emerged as a significant source and major focus for future drug development and human health care. Botanicals may be useful for treating or preventing metabolic syndrome because they often have a wide range of biologically active compounds that can work together to boost each other’s effectiveness or have a synergistic effect, giving more benefit than a single chemical substance. Some extracts of botanicals frequently contain natural active components that act on multiple biological targets, creating an opportunity to concurrently resolve multiple defects associated with metabolic syndrome. To find out if botanicals can be used to treat metabolic syndrome as a group, trials must be stratified to look at differences in disease severity, age, gender, and genetic variation in the sample populations

Acute Inferior Wall Myocardial Infarction due to Occlusion of the Wrapped Left Anterior Descending Coronary Artery

Acute occlusion of the left anterior descending coronary artery (LAD) generally results in ST segment elevations in precordial leads and reciprocal ST segment depression in inferior leads. The occurrence of isolated inferior myocardial infarction due to occlusion of LAD is very rare. We describe an isolated acute inferior myocardial infarction due to occlusion of a wrapped LAD at the apex which continues as the large posterior descending coronary artery (PDA) beyond the occlusion

Network pharmacology based pharmacokinetic assessment and evaluation of the therapeutic potential of catechin derivatives as a potential myostatin inhibitor: A special view on Sarcopenic Obesity

Sarcopenic obesity has become a significant age-related metabolic problem. Catechins are flavanol, derivatives which poses a strong antioxidant activity. The major components of catechin derivatives. were identified through our physicochemical and pharmacokinetic parameters estimation. Therefore, in this study, network pharmacology was used to explore the multiple targets related to Sarcopenia, Metabolic syndrome, and obesity. The targets were identified from network analysis. The catechin derivatives were screened using Lipinski’s rule of five, Veber scale, Egan scale, and Muegge scale. From this drugglikness property catechin and Epicatechin was selected which were docked towards the myostatin inhibition PDB ID: 3HH2. Furthermore, the computational docking method on Catechin and Epicatechin with the stronger interaction towards myostatin inhibition receptor with the binding energy of −6.90 kcal/mol. and −7.0 kcal/mol from autodock software, respectively, for catechin and Epicatechin. Higher binding energy confirms the pharmacotherapeutic activity of Catechin and Epicatechin toward the myostatin inhibitor target.</p